Released on = February 8, 2007, 12:48 am

Press Release Author = Cambridge Theranostics Limited

Industry = Biotech

Press Release Summary = Cambridge Theranostics Ltd (CTL), a biotech spin-out company
from Cambridge University, announced today a major deal that will allow CTL to
commercialize a novel pharmaceutical product that should provide substantial
benefits and health improvements in patients with coronary heart disease. CTL
intends to obtain rapid regulatory approval for this pharmaceutical product with a
view to launching it as soon as possible.

Press Release Body = Cambridge Theranostics Ltd (CTL), a biotech spin-out company
from Cambridge University, announced today a major deal that will allow CTL to
commercialize a novel pharmaceutical product that should provide substantial
benefits and health improvements in patients with coronary heart disease. CTL
intends to obtain rapid regulatory approval for this pharmaceutical product with a
view to launching it as soon as possible.

In the deal, signed in 2006, CTL licensed from Nestlé the rights to develop and
market pharmaceutical products based on an active ingredient that is a patented
formulation developed by the Nestlé Research Centre in Switzerland.

Commenting on the deal, Dr. Gunter Schmidt, CEO said "This deal represents a
significant milestone in the 4 year history of CTL. It provides a solid basis to
launch our first therapeutic product."Dr.

Ivan Petyaev, Founder CSO said "Having identified one of the key factors of
atherosclerosis, we were delighted to partner with Nestlé to develop CT003. This
substance is a powerful inhibitor of AtheroAbzymesT and exhibits an excellent safety
profile."Nestlé licenses Novel Heart Disease product to Cambridge Theranostics

About Cambridge Theranostics
Cambridge Theranostics Ltd. was founded in 2002 and is privately owned. CTL has
identified a new causative factor of lipid oxidation, which is a critical step in
the development of atherosclerosis, angina, coronary heart disease and stroke, but
which has hitherto not been targeted successfully for therapeutic intervention. The
newly discovered AtheroAbzymesT are a class of antibody that directly oxidise LDL
leading to the initiation or exacerbation of atherosclerotic plaque formation. The
new product is a potent inhibitor of AtheroAbzymeT and has demonstrated substantial
benefits and health improvements in patients with coronary heart disease. CTL has
also developed an AtheroAbzymeT diagnostic test that can be used to identify
patients with active atherogenesis even with asymptomatic ischemia. These tests can
also be used to select and monitor treatment of patients, with the AtheroAbzymeT
inhibitor licensed from Nestlé.

Web Site = http://www.cambridgetheranostics.co.uk/Press_Releases.html

Contact Details = Dr Gunter Schmidt, CEO Tel: +44 (0)7711704816
ghschmidt@cambridgetheranostics.co.uk